Reports related to this article:
Project(s): View 2 related projects in PECWeb
Plant(s): View 2 related plants in PECWeb
Released July 21, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--It was not very long ago that seemingly the only time Big Pharma had a major building announcement, it was for a plant closure or another round of layoffs. New builds were expected to come out of the emerging markets of Asia or Brazil, rather than the seasoned locations of the West, including Ireland.
Long prized as a jewel in the Big Pharma crown for production, the Emerald Isle took a hit in pharmaceutical-biotech employment and capital investment, as the industry began the long journey of reinventing itself. Yet industry boosters in Ireland never stopped believing that the tide would eventually turn. With its healthy infrastructure and an extremely educated available workforce, the bet was that as the industry sorted itself out, capital investment dollars would find their way back.
As they have, in a big way, with a consistent stream of pharmaceutical-biotech project activity. The investments range from a $900 million biologics plant that just kicked off construction in Dublin to a $2 million production warehouse addition. Regularly scheduled maintenance programs to keep the delicate and expensive equipment running optimally are of course in place.
Bristol-Myers Squibb (NYSE:BMS) (New York City, New York) shopped the nearly $1 billion project around globally before finally settling on a hundred-acre site adjacent to its existing active pharmaceutical ingredients (APIs) plant. The company will build a 300,000 square-foot, large-scale biological production facility, including six 15,000-liter bioreactors (90,000-liter total capacity) and purification area, which will manufacture multiple therapies from the company's growing biologics portfolio.
Shire Plc (NASDAQ:SHPG) (Dublin, Ireland) chose the city of Dunboyne for a $400 million investment to build a grassroot biologicals manufacturing plant. The decision to invest in the new facility was based on need for increased product demand, for both existing biological products and those still in the pipeline. The plant will be capable of both clinical and commercial scale production. An estimated 400 new jobs are expected to be created at the new facility.
Grifols (NASDAQ: GRFS) (Barcelona, Spain) will invest $85 million in Grange Castle, Clondalkin to build a new albumin purification unit. The expansion will add the capacity to produce between 130 and 150 million grams/year of albumin (Albutein). Albumin is used to replace blood volume loss resulting from trauma such as a severe burns or an injury that causes blood loss. Other conditions treated with the drug include low albumin levels caused by surgery, dialysis, abdominal infections and liver failure.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
Long prized as a jewel in the Big Pharma crown for production, the Emerald Isle took a hit in pharmaceutical-biotech employment and capital investment, as the industry began the long journey of reinventing itself. Yet industry boosters in Ireland never stopped believing that the tide would eventually turn. With its healthy infrastructure and an extremely educated available workforce, the bet was that as the industry sorted itself out, capital investment dollars would find their way back.
As they have, in a big way, with a consistent stream of pharmaceutical-biotech project activity. The investments range from a $900 million biologics plant that just kicked off construction in Dublin to a $2 million production warehouse addition. Regularly scheduled maintenance programs to keep the delicate and expensive equipment running optimally are of course in place.
Bristol-Myers Squibb (NYSE:BMS) (New York City, New York) shopped the nearly $1 billion project around globally before finally settling on a hundred-acre site adjacent to its existing active pharmaceutical ingredients (APIs) plant. The company will build a 300,000 square-foot, large-scale biological production facility, including six 15,000-liter bioreactors (90,000-liter total capacity) and purification area, which will manufacture multiple therapies from the company's growing biologics portfolio.
Shire Plc (NASDAQ:SHPG) (Dublin, Ireland) chose the city of Dunboyne for a $400 million investment to build a grassroot biologicals manufacturing plant. The decision to invest in the new facility was based on need for increased product demand, for both existing biological products and those still in the pipeline. The plant will be capable of both clinical and commercial scale production. An estimated 400 new jobs are expected to be created at the new facility.
Grifols (NASDAQ: GRFS) (Barcelona, Spain) will invest $85 million in Grange Castle, Clondalkin to build a new albumin purification unit. The expansion will add the capacity to produce between 130 and 150 million grams/year of albumin (Albutein). Albumin is used to replace blood volume loss resulting from trauma such as a severe burns or an injury that causes blood loss. Other conditions treated with the drug include low albumin levels caused by surgery, dialysis, abdominal infections and liver failure.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
